EUVIMEDEUVIMED entdecken
Open Access

Effects of anti‐tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria

Oscar B Akide Ndunge iD, Henry J Shikani, Minxian Dai, Brandi D Freeman, Mahalia S Desruisseaux iD

Journal of Neurochemistry · 2023-11 · 167 (3) · 441-460

DOI: 10.1111/jnc.15972 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurochemistry, online erschienen am 09.10.2023. Verfasst von Oscar B Akide Ndunge und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, Connecticut, New Haven, USA. Hauptthemen laut MEDLINE: Malaria, Cerebral, Neurodegenerative Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCATS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cerebral malaria (CM), a potentially fatal encephalopathy caused primarily by infection with Plasmodium falciparum, results in long‐term adverse neuro‐psychiatric sequelae. Neural cell injury contributes to the neurological deficits observed in CM. Abnormal regulation of tau, an axonal protein pathologically associated with the formation of neurofibrillary lesions in neurodegenerative diseases, has been linked to inflammation and cerebral microvascular compromise and has been reported in human and experimental CM (ECM). Immunotherapy with a monoclonal antibody to pathological tau (PHF‐1 mAB) in experimental models of neurodegenerative diseases has been reported to mitigate cognitive decline. We investigated whether immunotherapy with PHF‐1 mAB prevented cerebral endotheliopathy, neural cell injury, and neuroinflammation during ECM. Using C57BL/6 mice infected with either Plasmodium berghei ANKA (PbA), which causes ECM, Plasmodium berghei NK65 (PbN), which causes severe malaria, but not ECM, or uninfected mice (Un), we demonstrated that when compared to PbN infection or uninfected mice, PbA infection resulted in significant memory impairment at 6 days post‐infection, in association with abnormal tau phosphorylation at Ser 202 /Thr 205 (pSer 202 /Thr 205 ) and Ser 396–404 (pSer 396–404 ) in mouse brains. ECM also resulted in significantly higher expression of inflammatory markers, in microvascular congestion, and glial cell activation. Treatment with PHF‐1 mAB prevented PbA‐induced cognitive impairment and was associated with significantly less vascular congestion, neuroinflammation, and neural cell activation in mice with ECM. These findings suggest that abnormal regulation of tau protein contributes to cerebral vasculopathy and is critical in the pathogenesis of neural cell injury during CM. Tau‐targeted therapies may ameliorate the neural cell damage and subsequent neurocognitive impairment that occur during disease. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria, CerebralNeurodegenerative DiseasesAnimalsMiceHumanstau ProteinsNeuroinflammatory DiseasesDisease Models, AnimalMice, Inbred C57BLCognitionImmunotherapyBrain

Stichwörter der Autor:innen

Plasmodium bergheicerebrovascular congestionglial activationmemory impairmentneural damageneuroinflammation

Substanzen

tau Proteins

Autor:innen und Institutionen

  • Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, Connecticut, New Haven, USA.
  • Department of Pathology, Albert Einstein College of Medicine, New York, Bronx, USA.

ORCID-Profile: Oscar B Akide Ndunge, Mahalia S Desruisseaux

Förderung

  • NINDS NIH HHS
  • NCATS NIH HHS
  • NIAID NIH HHS
  • Wellcome Trust
  • Burroughs Wellcome Fund
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Neurological Disorders and Stroke
  • Yale University

Zitieren

APA

Akide Ndunge, O. B., Shikani, H. J., Dai, M., Freeman, B. D., & Desruisseaux, M. S. (2023). Effects of anti‐tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria. Journal of Neurochemistry, 167(3), 441-460. https://doi.org/10.1111/jnc.15972

Vancouver

Akide Ndunge OB, Shikani HJ, Dai M, Freeman BD, Desruisseaux MS. Effects of anti‐tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria. Journal of Neurochemistry. 2023;167(3):441-460. doi:10.1111/jnc.15972

BibTeX
@article{AkideNdunge2023,
  author = {Akide Ndunge, Oscar B and Shikani, Henry J and Dai, Minxian and Freeman, Brandi D and Desruisseaux, Mahalia S},
  title = {Effects of anti‐tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria},
  journal = {Journal of Neurochemistry},
  year = {2023},
  volume = {167},
  number = {3},
  pages = {441--460},
  doi = {10.1111/jnc.15972}
}
Kostenlos starten →